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CNRS), U 959 (INSERM), Paris F-75013, France; 12Liver Unit, University of Calgary, Calgary, Alberta, CanadaHCV has been classiﬁed into no fewer than six major geno- of subtypes [3]. Each HCV genotype is unique with respect to
types and a series of subtypes. Each HCV genotype is unique with
respect to its nucleotide sequence, geographic distribution, and
response to therapy. Genotypes 1, 2, and 3 are common through-
out North America and Europe. HCV genotype 4 (HCV-4) is com-
mon in the Middle East and in Africa, where it is responsible for
more than 80% of HCV infections. It has recently spread to several
European countries. HCV-4 is considered a major cause of chronic
hepatitis, cirrhosis, hepatocellular carcinoma, and liver transplan-
tation in these regions. Although HCV-4 is the cause of approxi-
mately 20% of the 170 million cases of chronic hepatitis C in
the world, it has not been the subject of widespread research.
Therefore, this document, drafted by a panel of international
experts, aimed to review current knowledge on the epidemiol-
ogy, natural history, clinical, histological features, and treatment
of HCV-4 infections.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Hepatitis C virus (HCV), a member of the Flavivirida family of
RNA viruses, is characterized by a high spontaneous mutation
rate with an estimated frequency of 1.4–1.9  103 mutations
per nucleotide per year [1,2]. As a result, HCV exists as a hetero-
geneous group of viruses sharing approximately 70% homology.
On the basis of nucleotide sequence homology, HCV has been
classiﬁed into no fewer than six major genotypes and a seriesJournal of Hepatology 20
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to therapy [4]. Genotypes 1, 2, and 3 are common throughout
North America and Europe. HCV genotype 4 (HCV-4) is common
in the Middle East and in Africa, where it is responsible for more
than 80% of HCV infections. It has recently spread to several Euro-
pean countries [5,6]. HCV-4 is considered a major cause of
chronic liver disease and cirrhosis, which leads to liver failure
and is the root cause of hepatocellular carcinoma. Because of
these complications, extended cirrhosis during chronic infection
is a primary cause of liver transplantation in these regions.
Although HCV-4 is the cause of approximately 20% of the 170
million cases of chronic hepatitis C in the world, it has not been
the subject of widespread research. Therefore, this document,
drafted by a panel of international experts, aimed to review cur-
rent knowledge on the epidemiology, natural history, clinical,
histological features, and treatment of HCV-4 infections.Epidemiology
Approximately 34 million people are chronically infected with
HCV-4. The Iinfection is common in the Middle East and Africa,
where it accounts for more than 80% of all hepatitis C cases [5–
8]. The risk factors for HCV-4 transmission are determined by
the geographical distribution of this genotype.
Egypt has the highest prevalence of HCV worldwide (15%) and
the highest prevalence of HCV-4, which is responsible for 90% of
infections, with a predominance of subtype 4a (55%) [5–9]. Epide-
miological and molecular evolutionary analysis on Egyptian
genotype 4a isolates suggest the origin of the HCV-4 epidemic
arises from the antischistosomal campaign, which was adminis-
tered parenterally, and only stopped in the mid-1960s [10,11].
However, other risk factors, mostly related to prevailing social
and cultural conditions, are responsible for maintaining the high11 vol. 54 j 1250–1262
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rates of HCV-4 transmission even after the treatment campaign
was stopped. Currently, the major route of transmission appears
to be health-related procedures with inadequately sterilized
instruments. Procedures performed by non-medical professionals
and traditional healers have been identiﬁed as important risk fac-
tors for HCV transmission in Egypt [12–14]. Intrafamilial and sex-
ual transmissions also play a role in the high prevalence of HCV-4
in this country [15,16].
The prevalence of HCV in Saudi Arabia is 1–3%, [17] with a
predominance of genotype 4 (62%). Unlike the predominance of
subtype 4a in Egypt, subtypes 4c/4d are the most prevalent sub-
types among Saudis, followed by subtypes 4h, 4e, and 4a, sug-
gesting that the origin and transmission of HCV-4 is different
from that in Egypt [17]. Similarly, studies from other parts of
the Middle East also suggest a high prevalence of HCV-4. For
example, 36–46% of HCV-infected Lebanese patients have HCV-
4 [18], 59% of Syrian patients [19] and 27% of HCV-infected Jorda-
nian patients on dialysis have HCV-4 [20].
HCV-4 is also endemic throughout Central and West African
countries such as the Congo, Liberia, and Uganda (where it
accounts for 100% of HCV infections), as well as Gabon, Tanzania,
and Cameroon (97%, 50%, and 36% of HCV infections, respectively)
[21–25]. Scariﬁcation, circumcision practices, and sexual trans-
mission may contribute to the persistence and propagation of
HCV transmission in these countries [21,25].
Recently, HCV-4 has become increasingly prevalent in some
southern European countries on the Mediterranean Sea, particu-
larly Italy, France, Greece, and Spain, where prevalence rates of
10–24% have been reported in some areas [26–31]. HCV-4 infec-
tion is frequent among intravenous drug users (IVDUs) (European
and non-European), HCV/HIV-coinfected patients, and immi-
grants from North and sub-Saharan Africa [26–31]. HCV-4 was
probably introduced into Europe through immigration and the
movement of IVDUs across European borders [31].
HCV-4 infections are uncommon in the United States, Canada,
South America, and Asia. The prevalence of HCV-4 in the United
States is about 1% [32]. Most HCV-4 cases reported from the Uni-
ted States were clustered among IVDUs or immigrants from
countries where subtype HCV-4 is known to be most prevalent
or among individuals who acquired the infection in these coun-
tries [32,33]. There are no reliable data on the prevalence of
HCV-4 either in Australia or in South East Asia. However, HCV-
4 appears to be rare in these regions.Natural history
There are few data on the natural history of HCV-4. It is likely
that the course of genotype 4 infection is similar to that of other
genotypes [25,34].
HCV-4 represents more than 30% of the annually reported
acute hepatitis cases in Egypt [35]. Very few studies address
the outcome of acute HCV-4 infection. Indeed, prospective stud-
ies have shown 20–50% rates of spontaneous resolution in acute
HCV-4 infections [36–38]; whereas those rates are reduced in
patients with a coinfection with HIV or Schistosoma mansoni, as
frequently occurs in Egyptians [34,37]. The presence of schistoso-
miasis is a negative predictor of outcome, being associated with
accelerated progression of hepatic ﬁbrosis among HCV-4 patients.
In fact, the ﬁbrosis progression rate of 0.1 ± 0.06 ﬁbrosis units/
year observed in HCV-4 patients (similar to that of patientsJournal of Hepatology 2011infected with other genotypes) increased up to 0.6 ± 0.13 in
patients with associated schistosomiasis [39–43]. An Egyptian
origin was independently associated with severe ﬁbrosis in two
French studies, however the higher ﬁbrosis scores in these stud-
ies might be attributed to concomitant schistosomiasis in these
Egyptian patients rather than ethnicity or HCV subtype [39,40].
Insulin resistance was also found to be correlated independently
with severity of ﬁbrosis [40]. The known association between
hepatocellular carcinoma (HCC) and HCV needs to be weighed
against other potential risk factors for HCC like schistosomiasis
and exposure to aﬂatoxins or pesticides [44–47].
Utility of liver biopsy and noninvasive ﬁbrosis tests
The biopsy is assessed for grade and stage of the liver injury, but
also provides information on other histological features that
might have a bearing on liver disease progression [48]. The two
more common non-HCV conditions that might affect disease pro-
gression and possibly impede treatment response are steatosis
[49,50] and excess of hepatocellular iron [51]. The pathological
ﬁndings in chronic HCV-4 are in general similar to other types
of viral hepatitis C. However, certain features may be prominent
in this genotype, one of which is the presence of moderate to
severe steatosis [50,52,53] with no associated sinusoidal ﬁbrosis
[53]. Host and viral factors contribute to the development of ste-
atosis in hepatitis C, but their relative importance varies with
genotype [54–56]. Hepatic steatosis in patients infected with
HCV-4 is mainly associated with metabolic factors and follows
the same pattern as those infected with genotype 1 [50,54]. Ste-
atosis, in particular moderate-to-severe steatosis was detected in
similar proportions of patients with genotype 1 and 4 [50,52,54].
Several studies have shown that steatosis in chronic HCV-4 is
macrovesicular [50,52,53] and is seen without any prominent
zonal preference [53]. More detailed studies are needed to deter-
mine if there is a characteristic histological pattern that might
distinguish chronic HCV-4. Efforts are ongoing to seek alternative
means focusing on noninvasive blood marker panels. In a recent
study, the combination of hyaluronic acid, YKL-40, platelet count
and serum aminotransferases provided information about the
amount of hepatic inﬂammation and steatosis in Egyptian
patients and achieved this cost-effectively [57].
Hepatocellular carcinoma
HCC is a major cause of cancer death worldwide [58], with evi-
dence that its incidence has sharply increased in many countries
as a consequence of the accumulation of patients with chronic
liver disease caused by viral hepatitis or alcohol abuse [58,59].
The incidence of HCC in Egypt is also increasing [60–62] and is
now the second most frequent cause of cancer and cancer mortal-
ity among men [63]. Hospital based studies have reported an
increase in the relative frequency of all liver-related cancers in
Egypt (>95% as HCC), from 4.0% in 1993 to 7.3% in 2003 [60–62].
Data from the National Cancer Registry of Egypt, the National
Cancer Institute and the Middle East Cancer Consortium recently
reported that the incidence rate among males was 7 times greater
than the next highest rate (among Israeli Jews) and more than
3 times that reported in the United States Surveillance Epidemi-
ology and End Results summary [63,64].
A possible association has been suggested between HCV-4 and
HCC based on the similarity of distribution of HCC and HCV-4 invol. 54 j 1250–1262 1251
Sample 
size 
Study design Treatment and duration
12 Open-label, 
uncontrolled pilot 
study 
PEG-IFN -α-2b (1.5 mcg/kg/wk) + 
RBV (15 mg/kg/d) x 48 wk 
or PEG -IFN-α-2b (1.5 mcg/kg/wk)
+ RBV (1000 mg or 1200 mg/d if ≤ or 
>75 kg, respectively) x 48 wk 
226  Prospective  PEG-IFN- -2a (180 mcg/wk) 
131 Prospective PEG-IFN- -2b (1.5 mcg/kg/wk)   
+ RBV (800 mg for <50 kg, 
1000 mg for 50-65 kg, 
1200 mg for 65-80 kg, 
1400 mg for  >80 kg) x 48 wk 
97 Prospective, 
randomized. 
PEG-IFN +
RBV+ pioglitazone  
in patients with
2>RI-AMOH
Arm A: PEG-IFN-α-2b (1.5 mcg/kg/wk) 
+ RBV (1000 mg or 1200 mg/d) if ≤ or 
+ RBV (1000 mg or 1200 mg/d) if ≤ or 
+ RBV (1000 mg or 1200 mg/d) if ≤ or 
+ RBV (1000 mg or 1200 mg/d) if ≤ or 
>75 kg respectively  + pioglitazone 30 mg/d 
>75 kg respectively  x 48 wk
>75 kg respectively  x 48 wk
>75 kg respectively  x 48 wk
>75 kg respectively  x 48 wk
Arm B: PEG-IFN- -2b (1.5 mg/kg/d)   
95 Prospective 
lebal-nepo
PEG-IFN -2a (180 mcg/wk) 
+ RBV ≥11 mg/kg/d x 48 wk
240
82 (34%) 
HCV-4
Retrospective PEG-IFN -2a  (180 mcg/wk)
or PEG-IFN-α-2b (1.5 mcg/kg/wk) 
+ RBV (1200 mg/d) x 48 wk
58 Retrospective PEG-IFN- -2b (1.5 mg/kg/wk) 
30 Prospective  
lebal-nepo
PEG-IFN- -2a (180 mcg/wk) 
Country 
Kuwait
Europeans 35%, 
Africans 24%
Egyptians 40%, 
Egypt 
Egypt 
Egypt 
Saudi Arabia   
Greece 
Middle East 
EVR
(%)
83
74
RVR: 34.3
cEVR: 64.8
RVR: 
271 vs. 6.1
EVR: 
68.7 vs. 48.9
NA 
NA 
63.8
83.3%
ETR
(%)
83
64
NA 
66.6 vs. 
44.89
69.5
NA 
NA 
NA 
SVR
(%)
75
54
60.3
60.4 vs. 
38.7
61.1
64
53.4
63.3
Ref.
[76]
[40]
[77] 
[78]
[79]
[80]
[81]
[82] 
96 Prospective, 
randomized.
PEG-IFN +
RBV +  
nitazoxanide
[83] 
(NTZ)
66
84
308
Prospective, 
response-guided
therapy
Prospective
Prospective, 
therapy
PEG-IFN-  -2a + RBV x 48 wk (n = 40); 
NTZ monotherapy x 12 wk followed by 
NTZ + PEG-IFN- -2a 
NTZ + PEG-IFN- -2a x 36 wk (n = 28); 
NTZ monotherapy x 12 wk followed by
+ RBV x 36 wk (n = 28) 
PEG  -2a (180 µg/wk)
+ RBV 1000 or 1200 mg/d
according to virological response at wk:
4 x 24, 48, 72 
PEG-IFN- -2a (180 mcg/wk) +
RBV (1000-1200 mg/d) if ≤ or
-NFI-GEP -2b  (1.5 mcg/kg/wk) 
+ RVB 10.6 mg/kg/d for either a fixed
 duration of 48 wk (control group) 
or a variable duration at 24, 36, 48 wk 
Egypt 
Austria 
Qatar 
Egypt  
RVR: 
38, 54, 64
cEVR: 
70, 68, 86
RVR: 45 
NA 
22 RVR,
cEVR 26,
pEVR 52
75, 
71,
82
NA 
77  
90 : 24 W
86 : 36 W
70 : 48 W
[84] 
[85]
[53]
50, 61, 79
87
67.9
88 : RVR
87 : cEVR
64 : pEVR
response-guided 
Table 1. Summary of studies of PEG-IFN-a in patients with chronic HCV-4.
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Sample 
size 
Study design  Treatment and 
duration
yrtnuoC EVR
(%)
ETR
(%)
SVR
(%)
Ref.
242
37
081
Retrospective  
non randomized 
yduts
Randomized  
htiwstneitap(
foyrotsih
bilharziasis)  
randomized  
PEG-IFN- -2b (1.5 mcg/kg/wk) +
kw84x)d/gm0021-0001(VBR
PEG-IFN- -2a  (180 µg/wk) +
;)83=n(,kw84xd/gm0021VBR
IFN- -2b 3 MU/tiw + RBV 1200 mg/d 
x 48 wk (n = 35) 
Prospective non -NFI-geP -2b  (100 µg/wk)  
RBV (1000-1200 mg/d)  x 48 wk (n = 40);
Peg-IFN- -2b (100 µg/wk) + 
RBV 1000-1200 mg/ d x 24 wk  (n = 70); 
IFN-  -2b 3 MU + RBV 1000-1200 mg/d
+ amantadine 200 mg/d, x 24 wk (n = 70)
,hcnerF
Egyptian, 
African 
rataQ
tpygE
AN
AN
72.5, 72.9,  
3.45
AN
Peg-IFN vs. Peg-IFN vs.
non-peg-IFN non-peg-IFN
(76.3 vs. 40; 
p = <0.002)
65.0, 65.7,  
1.74
[39]
[86]
[87]
Egyptian: 48
French: 37  
African: 25
(65.8 vs.25.7
p <0.05)
55.0, 48.6, 
28.6 
I and II:   
I and III: 
(p = 0.006), 
(p = 0.015) 
(p = 0.517),
II and III:
062
66
001
Prospective,
double-blind,
randomized 
Prospective,
lebal-nepo
Open-label  
PEG-IFN- -2 b  (1.5 mcg/kg/wk) + 
RBV (1000-1200 mg/d) for 24, 36, 48 wk
-NFI-GEP -2 b  (1.5 mcg/kg/wk) +
)d/gm0021-0001(VBR+ x 48 wk
PEG-IFN- -2a  (180 µg/wk) +
d/gm0021VBR x 48 wk (n = 51)
IFN-  -2a 3 MU + RBV 800-1000 mg/d
(n = 49) x 48 wk
tpygE
52% Egyptian; 
remainder 
Kuwaiti and 
Syrian
naitpygE
69, 68, 69  
78
NA
48, 68, 70  
77
AN
[88] 
[89]
]73[
29, 66  
86
96
cohtsoP89
HCV-4 patients
from two large
PEG-IFN- -2a  Study 1: (180 mcg/wk) +
RBV 1000-1200 mg/d  x 48 wk (n = 13)
(180 mcg/wk) + PEG-IFN- -2a  Study 2: 
RBV 800-1200 mg/d x 24 or 48 wk
High -dose RBV (n = 24) 
Low-dose RBV (n = 8)
Low-dose RBV (n = 5)
High-dose RBV (n = 12)
ANlanoitanretnI AN ,36,97
67, 0
[90]
analysis of 
RCTs
95
081
091
Randomized,
parallel-group
Open-label  
multicenter 
Prospective, 
open-label RCT
PEG-IFN- -2b  (100 mcg/wk) +
RBV 800 mg/d x 48 wk (n = 28) ,
IFN- -2b 3 MU+ 
RBV 800 mg/day x 48 wk (n=31)
PEG-IFN-  2a- (180 µg/wk) + 
)d/gm008(VBR
PEG-IFN-  2a )kw/gµ081(-
IFN- -2a 4.5 MIU tiw 
+ RBV (800 mg/d) x48 wk 
(100 mcg/wk) + RBV (800 or 1000 mg 
kw84x)spuorghtobrof
IFN -  -2b 3 MU tiw b2N-FI-GEPro -
Saudi Arabia
Saudi and 
Egyptian
tpygE
AN
77, 60, 43
AN
67.9
54.8
67, 59, 37
AN
9.24
3.23
50, 28, 
03
55
04
[91]  
[74] 
[75]
Table 1 (continued)
Abbreviations: Wk: week, d: day, x: for treatment duration, HOMA-IR: homeostasis model assessment index NA: no available data, EVR, early virologic response; RVR: rapid
virologic response, ETR: end of treatment response, PEG-IFN, pegylated interferon; RBV, ribavirin; SVR, sustained virologic response.
JOURNAL OF HEPATOLOGY
Journal of Hepatology 2011 vol. 54 j 1250–1262 1253
Table 2. Outcome by virological response at weeks 4 and 12 in genotype four patients treated for 48 weeks with peginterferon alfa-2 plus ribavirin.
Week 4 Week 12Study  N 
Kamal [53]  387 
Ferenci et al. [84]  66 
RVR, n (%) 
77 (19.9) 
30 (13.3) 
SVR, n (%) 
66 (86) * 
26 (96) * 
EVR, n (%) 
275 (71) 
28 (56) 
SVR, n (%) 
**)46(071
**)64(31
Abbreviations: EVR = early virological response (HCV RNA < 50 IU/ml or 2 log drop in viral load); RVR = rapid virological response (HCV RNA < 50 IU/ml); SVR = sustained
virological response (HCV RNA < 50 IU/ml); ⁄Patients were treated for 24 weeks; ⁄⁄Patients were treated for 48 weeks or longer.
* High basal viral load (≥800,000),
 Advanced degree of fibrosis (≥F3,4),
  High degree of basal insulin resistance (HOMA-IR ≥2)
Check HCV-RNA 
at week 4
Check HCV-RNA at week 12
Check HCV-RNA 
at week 24
 No RVRRVR
Predicators of poor response *
No Yes
24 weeks 
therapy
48 weeks 
therapy
48 weeks 
therapy
72 weeks 
therapy
<2 Log
decline
>2 Log
decline Negative
Negative Positive
STOP STOP
Fig. 1. A proposed algorithm for treating patients with chronic HCV-4 based on the kinetics of viral response (response-guided therapy). RVR, rapid viral response.
ReviewEgypt [63–68]. A recent meta-analysis showed that more than
84% of Egyptian patients with HCC are positive for HCV-4 [68].
A signiﬁcant association seems to exist not only with the most
prevalent subtype 4a, but also with subtype 4o [44] even though
this association has not been conﬁrmed by others [69]. Other fac-
tors related to HCC development may play a role, such as coinfec-
tion with schistosomiasis which is known to increase risk of HCC
[4,66], exposure to pesticides [47], and dietary aﬂatoxins [70].
Evolution of treatment
Combination therapy with pegylated interferon alpha and ribavi-
rin represents the current standard of care in chronic HCV-4.
Interferon (IFN) based therapies were introduced in chronic hep-
atitis C in the 1980s and have improved dramatically over the
subsequent years. With conventional IFN-a monotherapy the
SVR rates were very poor, similar to those achieved in HCV geno-
type 1 infection, ranging between 5% and 25% [71,72]. However,
with the addition of ribavirin to conventional IFN-a, SVR rates1254 Journal of Hepatology 2011increased to 25–42% [73,74], about intermediate between those
achieved in HCV-1 and HCV-2 or HCV-3. With the introduction
of pegylated IFN compounds in combination with ribavirin, the
efﬁcacy of treatment in HCV-4 further improved signiﬁcantly. In
various studies from European and Middle Eastern countries,
SVR rates ranging from 43% to 70% were reported [39,40,53,75–
88,73,89–91] (Table 1). These results are indeed higher than those
(42–46%) achieved in genotype 1 patients but still lower than
those (76–82%) reported in chronic hepatitis C genotype 2 and 3.
Studies looking at predictive factors on HCV-4 patients are rel-
atively scarce. Negative predictive factors at baseline include high
viral load, presence of cirrhosis and steatosis, insulin resistance,
IL-28B polymorphism TT, and HIV coinfection [75,86,73,91–93];
these factors are associated with a lower SVR. A rather unex-
pected ﬁnding of the therapeutic trials in HCV-4 has been that
under the same treatment regimen, patients from Egypt and
the Middle East experienced higher SVR rates than patients from
Europe or Africa. In a French retrospective study, conducted in
242 HCV-4 patients from various geographical areas (40% Egyp-vol. 54 j 1250–1262
Table 3. Summary of studies on combined therapy in HCV-4 patients with incomplete (F3) or complete (F4) cirrhosis.
First Author, 
year [Ref.]  
n Therapeutic regimen Duration 
(wk) 
SVR, n 
(%) 
Liver histology
Hasan, 
]73[,4002
20 PEG-IFN-α 2b 1.5 mcg/kg/wk 
RBV 1000-1200 mg/d 
48  30.0 F3-F4 
Derbala,  
]401[,5002
12 PEG-IFN-α 2b 1.5 mcg/kg/wk 
RBV 800-1200 mg/d 
48   8.3 F4 
Derbala,  
]68[,6002
13 PEG-IFN-α-2a 180 mcg/wk 
RBV 1200 mg/d 
52  38.5 F3-F4 
Males,  
]501[,7002
14 PEG-IFN-α-2a 180 mcg/wk 
RBV  11 mg/kg/d 
48   35.7 F4 
Kamal,  
]35[,7002
27 PEG-IFN-α-2b 1.5 mcg/kg/wk 
Ribavirin 10.6 mg/kg/d 
24-48  0 F4 
Roulot,  
]93[,7002
76 PEG-IFN-α-2b 1.5 mcg/kg/wk 
RBV 1000-1200 mg/d 
48  31.6 F3-F4
Ferenci,  
]48[,8002
4 PEG-IFN-α-2a 180 mcg/wk 
RBV 1000-1200 mg/d 
48  75.0 F3-F4 
Gad, 
]601[,8002
78 PEG-IFN-α-2a 180 mcg/wk, PEG-IFN-α-2b 
1.5 mcg/kg/wk, standard IFN-α-2b 3 MU 
thrice/wk, RBV 1000-1200 mg/d 
48  37.2 F3-F4 
El Makhzangy, 
2009 [79] 
33 PEG-IFN-α-2a 180 mcg/wk 
RBV  11mg/kg/d 
48  45.5 F3-F4 
Giannini,  
]701[,9002
5 PEG-IFN-α-2a  180 mcg/wk, PEG-IFN-α-2b 
1.5 mcg/kg/wk, RBV 800-1200 mg/d 
48  0 F4 and portal 
hypertension
Abbreviations: Wk: week, d: day, n = number, PEG-IFN, pegylated interferon; RBV, ribavirin; SVR, sustained virologic response.
JOURNAL OF HEPATOLOGYtians, 35% Europeans, and 24% Africans) the respective SVR rates
were 54.9%, 40.3%, and 32.4%. Egyptian origin and the absence of
severe ﬁbrosis were found to be independently associated with
SVR [39]. It remains unclear whether the difference in SVR is
related to ethnicity, HCV-G4 subtype, the mode of transmission
or IL-28B genotype [93].
Similar results have recently been reported in a prospective
study of HCV-4 patients from Europe, France, and Africa with
respective SVR rates of 63%, 51%, and 39% and an overall SVR per-
centage of 54%. Despite the presence of severe ﬁbrosis in a large
proportion of the Egyptian patients, Egyptian origin was again
independently associated with SVR (p = 0.001); OR: 5.87 (95%
CI: 2.75–12.55) (p = 0.001). SVR was also independently associ-
ated with insulin resistance measured by the homeostasis model
assessment index (HOMA-IR)<2 (p = 0.001) and by non-severe
ﬁbrosis (p = 0.001) [40]. Moreover, in another trial from Egypt,
HOMA-IR was found to be a predictor not only of SVR but also
of rapid virologic response (RVR) (p = 0.002 and 0.0041; respec-
tively) [77]. The use of insulin-sensitizing agents such as pioglit-
azone in conjunction with HCV-4 treatment increases both SVR
and RVR rates [78]. HCV kinetics under therapy has been found
to be extremely useful to predict SVR [53,88]. Other factors dur-
ing treatment are patients’ compliance and no dosage reductions
or dose fulﬁlled with 80/80/80 [94].
IL28B polymorphism
A genome wide association study in patients infected with
HCV-1 revealed a single nucleotide polymorphism (SNP)-Journal of Hepatology 2011rs12979860 in the IL-28B region on chromosome 19
(19q13.13), associated with a more than twofold increased rate
of SVR [95]. In a multivariate analysis of HCV-4 patients, base-
line viral load, ﬁbrosis and the IL28 (rs8099917 T/T allele) (OR:
0.124, 95% CI: 0.030–0.505) were signiﬁcantly associated with
SVR [95]. The strongest predictor for the ﬁnal outcome was
RVR (OR: 26.00; 95% CI: 7.148–94.545, p <0.0001). If RVR was
included into the multivariate model, only the RVR and the
ﬁbrosis score remained signiﬁcant. Thus, determination of
IL28B polymorphism may not be useful to select patients with
HCV-4 for abbreviated treatment schedules. However these
data need further conﬁrmation.
Duration of treatment
The duration of treatment is based on HCV genotype in current
guidelines [96,97]. Forty-eight-week regimens are recommended
for patients infected with HCV-1 and 4. This recommendation is
based on the results of large randomized, international, phase
III trials of peginterferon alfa-2 combined with ribavirin [98–
100]. Unfortunately these studies included very few patients with
HCV-4.
Measurement of the virological response at 4 and 12 weeks
of therapy is a simple and reliable tool that allows the treat-
ment regimen to be tailored to the individual. Patients who
become HCV-RNA negative (<50 IU/ml by qualitative PCR
assay) or have a P2 log10 drop in serum HCV RNA level by
quantitative PCR assay after 12 weeks of therapy are deﬁned
as having an early virological response (EVR). Failure tovol. 54 j 1250–1262 1255
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achieve an EVR can predict which patients are unlikely to have
a successful outcome with combination therapy. Those who
are HCV-RNA negative after 4 weeks of treatment are deﬁned
as having a RVR. In contrast to EVR, RVR predicts which
patients are most likely to have a successful outcome with
combination therapy.
The probability of SVR increases with the speed of viral load
decline. For example, a higher proportion of patients with HCV-
1 who become HCV-RNA negative after 4 weeks of treatment
will achieve an SVR than those who become HCV-RNA negative
after 12 weeks of treatment [101]. SVR rates were much lower
in patients who did not clear HCV RNA during the ﬁrst
12 weeks of treatment. A completely negative test for HCV
RNA at week 12 (complete EVR) is a better predictor of an
SVR after 48 weeks of combination therapy than a partial
EVR (P2 log10 drop in serum HCV RNA at week 12). Those
who achieved an RVR had an SVR rate of 91%, those who
achieved a complete EVR had an SVR rate of 75%, and among
the 22% of patients with a partial EVR and virus negative by
week 24 only 27% achieved an SVR [101].
Response-guided therapy
There are only two randomized controlled trials in patients with
HCV-4 reporting viral response at week 4 (Table 2). Patients with
HCV-4 who achieve an RVR are potential candidates for abbrevi-
ated 24-week treatment regimens; provided that no other predic-
tors of poor response (Fig. 1). [53,84]. Response rates are similar
to those treated for 48 weeks [87]. The prospect of shorter treat-
ment for these patients is appealing because the overall tolerabil-
ity is likely to be better and the costs lower with an abbreviated
treatment regimen; conversely, slow responders who do not
achieve HCV RNA negativity by week 4 or 12 are potential candi-
dates for prolonging treatment up to 72-weeks. Only one ran-
domized study examined prolonged 72-week regimens in HCV4
patients [102] but the number of patients was too small to draw
any conclusions.
Fig. 1 presents a proposed algorithm for treating patients
with chronic HCV-4 based on the kinetics of viral response
(response-guided therapy). In conclusion, measurement of
RVR and complete/partial EVR is a simple and reliable tool that
allows clinicians to estimate the likelihood of an SVR and to
individualize the duration of treatment. Unfortunately, in con-
trast to patients with HCV-1 the concept of response-guided
therapy has not been validated in patents with HCV-4. In the
current absence of any ﬁrm data on HCV-4 patients, we sug-
gest that similar response-guided approaches used in HCV-1
patients may be considered. Thus those with an RVR are highly
likely to achieve SVR and are candidates for abbreviated, 24-
week regimens. Patients with a complete EVR at week 12 have
a high probability of achieving an SVR with a 48-week regi-
men. Patients with a partial (slow) EVR (no RVR and detectable
HCV RNA but >2 log10 drop at week 12 and virus negative at
week 24) may be considered for treatment prolongation to
72 weeks, if they can tolerate this.
Treatment in special populations
Cirrhosis
Treatment of compensated cirrhosis is a relevant issue since sus-
tained HCV clearance is associated with a better survival, reduced1256 Journal of Hepatology 2011HCC occurrence and absence of decompensation [103]. However,
severity of liver ﬁbrosis and HCV genotype are the two major
determinants of SVR. The published data on the efﬁcacy of Peg-
IFN and ribavirin in cirrhotic patients infected by HCV-4 are lim-
ited (Table 3) [39,53,79,84,86,73,104–107]. Overall the cumula-
tive response rate is about 30% of treated patients, but this
ﬁgure includes also incomplete cirrhosis, or F3, that probably
overestimates the real treatment efﬁcacy in cirrhotic patients.
HIV coinfection
It has been reported that the prevalence of HCV-4 among
HIV-infected individuals is at least 15% of all anti-HCV posi-
tive subjects [108]. Data derived from two trials showed that
among 75 HIV-infected patients with HCV-4 treated with Peg-
IFN alfa-2a plus ribavirin, only 21 (28.0%) achieved SVR [92].
The major factor of low rate of response was related to pre-
mature treatment discontinuation due to severe adverse
effects.
Hemodialysis
The prevalence of HCV infection in patients with end stage
renal disease is highly variable ranging from 3% to 80%
between different countries and centers [109]. HCV-4 infected
subjects have a shorter graft survival after kidney transplanta-
tion due to increased risk of severe infection and liver disease
deterioration. As a consequence, the current recommendation is
to give antiviral therapy before transplantation with the aim to
eradicate the infection. However the use of Peg-IFN and ribavi-
rin in dialysis patients is hampered by fairly frequent side-
effects [110]. Two recent meta-analyses have shown that the
overall SVR after Peg-IFN with or without ribavirin was 40%,
including 33% for genotype 1 [111]. No data on efﬁcacy of
combined therapy in patients infected by genotype 4 are avail-
able so far.
Children/adolescents
Combination therapy with Peg-IFN-alpha and ribavirin treatment
is effective in children with chronic hepatitis C [112,113] with
SVR rates across different genotypes comparable to adults. One
study reported the results of Peg-IFN plus ribavirin treatment
in 12 adolescents infected by genotype 4 [76]. Nine patients
(75%) achieved SVR suggesting that combination therapy is effec-
tive in this clinical context.
Acute hepatitis C
Scant data are available about the optimal treatment regimen in
acute HCV-4 and demonstrated a high SVR with IFN-based ther-
apies compared with no treatment [37,114,115]. The available
clinical trails showed that acute hepatitis patients infected with
HCV-4 have higher rates of SVR compared with HCV-1 infections.
In one study [116], an SVR was achieved in 60% and 88% of geno-
type 1 patients and in 93% and 100% of HCV-4 patients after 12
and 24 weeks of treatment, respectively [37].Thalassamia major
Few data are available on the treatment of HCV-4 in patients with
thalassamia. Current literature is lacking sufﬁcient evidence
about the use of PEG-IFN as monotherapy or in combination with
ribavirin in thalassamic patients. Inati et al. evaluated in a ran-
domized study [117] the safety and efﬁcacy of PEG-IFN-a withvol. 54 j 1250–1262
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or without ribavirin therapy in 20 patients with thalassamia and
HCV-4. An SVR was achieved in (30% and 62.5%; p = 0.19) in the
monotherapy and combination groups, respectively. They
reported an increase in the transfusion requirements by 34% in
the combination group (p = 0.08). In another study, Kamal et al.
[118] reported that the overall SVR rates were (46% and 64%)
with PEG-IFN alfa-2b vs. PEG-IFN alfa-2b plus ribavirin combina-
tion therapy, respectively. However, the reported adverse events
were more frequent with combination therapy than with PEG-
IFN alfa-2b alone.
Liver transplantation
End-stage liver disease secondary to HCV infection is the major
indication for orthotopic liver transplantation (OLT) worldwide
[119]. The percentage of HCV-4 patients among recipients of
OLT varies depending on the geographic location from around
29% in Saudi Arabia [120] to more than 90% in Egypt, [121] while
it represents a relatively uncommon indication in the western
world [122,123].
The natural history of HCV-4 re-infection after liver transplan-
tation is inadequately described in the literature. Re-infection of
the graft with HCV is universal after liver transplantation regard-
less of the genotype, leading to an accelerated course of liver
injury in many cases [124]. Most studies conducted worldwide
have investigated disease recurrence in HCV genotypes 1, 2,
and 3 [119]. However, there are few reports on post-OLT recur-
rence of HCV-4.
Four studies have been reported from liver transplant centers
in Europe and Australia. Gane et al. reported on 14 patients with
recurrent HCV-4 post-OLT and found that about 50% of these
patients have progressive liver disease [125]. They also found
that patients infected with genotypes 1b and 4 had the worst out-
comes, while genotype 2 and 3 patients had less severe disease
recurrence. Similarly, an analysis of 182 patients transplanted
for HCV in Australia and New Zealand (16 of whom had HCV-4)
found that among the many factors studied in univariate and
multivariate analyses, genotype 4 was associated with an
increased risk for re-transplantation and death [123]. By contrast,
a study from another Australian center, including patients with
HCV-4, showed that genotype 1b, but not 4, was associated with
higher recurrence rates after transplantation [126]. In a more
detailed study from the UK, 32 of 128 patients who underwent
OLT for hepatitis C were infected with HCV-4 [122]. A statistically
signiﬁcant greater ﬁbrosis progression rate was observed in HCV-
4 patients compared to non-genotype-4, although their rates of
survival were similar. The authors attributed the difference
between these two groups to the signiﬁcantly older donor age
in the HCV-4 group and the ethnic background of these patients
(predominantly Egyptian). On the other hand, studies from the
Middle East show a more favorable outcome of HCV-4 patients.
In a study from Saudi Arabia on biopsy proven recurrence HCV
post-OLT there were no signiﬁcant differences between genotype
1 and 4 patients in terms of epidemiological, clinical, and histo-
logical factors as well as outcome (patients and graft survival)
[127]. Among many epidemiologic, laboratory, virologic factors
included in that analysis, the only factor predictive of an
advanced histological score was the HCV RNA level at the time
of biopsy.
In Egyptian studies of living-related liver transplantation of
HCV-4 patients a similar good outcome was observed. HCV clini-
cal recurrence was observed in 31% of patients and was mostlyJournal of Hepatology 2011mild, as 91% of patients had ﬁbrosis scores less than F2 [128]. After
36 months of follow-up, 91% of patientswere alivewith good graft
function. Similar to the study from Saudi Arabia, recurrent HCV
was associated with pre-transplant and post-transplant viral load
and to the presence of antibodies to hepatitis B core antigen.
Published studies on the response rates and outcome of
antiviral therapy in patients with HCV-4 post-OLT are lacking.
In an abstract from Saudi Arabia, 25 patients infected with
HCV-4 were treated with PEG-IFN alfa-2a at a dose of
180 lg/week plus ribavirin 800 mg/day, (dose was adjusted as
tolerated range 400–1200 mg) [129]. Fourteen patients (56%)
achieved sustained virological response (SVR). The results of
this study suggest that the post-transplant treatment outcome
in HCV-4 is probably better then genotype 1 and less favorable
than genotypes 2 and 3. This response pattern among the dif-
ferent genotypes parallels the response pattern in the immuno-
competent population.
More studies are warranted to further understand HCV4 and
OLT and to establish effective strategies for limiting the progres-
sion of liver disease post-OLT in HCV-4 patients.
Novel treatments
In spite of the improvement of chronic hepatitis C treatment over
the last two decades, treatment with PEG-IFN and ribavirin is still
associated with frequent and sometimes severe side effects and
many patients cannot be treated because of contraindications
[130]. A major step forward in the therapy of HCV infection is
expected by the approval of new direct inhibitors of HCV replica-
tion. Several compounds, mainly inhibitors of the HCV NS3/4A
protease and NS5B polymerase, are currently in phase II and III
trials and the ﬁrst HCV protease inhibitors will hopefully be
licensed in 2011–2012. [131,132]. The large majority of the
new antiviral drugs are currently developed only for HCV-1 infec-
tion. The most advanced compounds in clinical development are
two protease inhibitors: telaprevir (VX950) and boceprevir
(SCH503034). Telaprevir has shown an improvement of SVR rates
in treatment naive HCV-1 patients to almost 70% and up to 40% in
previously unresponsive patients [133,134]. In a proof of concept
study, telaprevir has also shown activity against HCV-4 during
15 days monotherapy or combination with Peg-IFN and RBV
compared to Peg-IFN, RBV and placebo [134]. Boceprevir is effec-
tive in HCV-1 patients [135], however, preclinical data suggests,
that boceprevir might not be effective in HCV-4 with the cur-
rently used dosages [136], and data on boceprevir in HCV-4
patients haves not been published. R7128 is another nucleoside
analog polymerase inhibitor that has demonstrated potent antivi-
ral activity. In a recent interim analysis at week 12; the combina-
tion of R7128 (1500 mg twice daily) plus Peg-IFN a-2a and
ribavirin in treatment-naive patients with HCV-1 and 4; R7 128
has show high rates of early viral response with promising safety
proﬁles and low rates of resistance or breakthrough [137].
Further data haves been published for two other compounds
with different mode of actions, nitazoxanide (NTZ) and Debio
025. NTZ, a synthetic antiprotozoal agent, is licensed in the Uni-
ted States for the treatment of infections with Cryptosporidium
parvum and Giardia lamblia. Antiviral properties of this compound
were discovered when patients with acquired immune deﬁciency
syndrome (AIDS) coinfected with hepatitis B and C were treated
for cryptosporidiosis. As a potential mechanism of action, NTZ
activates the protein kinase activated by double-stranded RNAvol. 54 j 1250–1262 1257
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(PKR), a key kinase that regulates the cell’s innate antiviral
response [138]. These observations could explain the clinical
antiviral effect of NTZ. In this context, two clinical studies are
of interest. A pilot trial explored NTZ monotherapy in Egyptian
hepatitis C patients infected with HCV-4. HCV-RNA became
undetectable in seven out of 23 patients who all had a rather
low viral load before treatment (6400,000 IU/ml). Interestingly,
four patients achieved SVR after 24 weeks of NTZ treatment
[139]. A recent study by Rossignol et al. explored the combination
of NTZ and standard PEG-IFN/RBV combination therapy in Egyp-
tian HCV-4 infected patients [93]. The trial was conducted in two
Egyptian centers and included 96 treatment-naïve patients – all
were infected with HCV-4. Patients were randomized in one of
three arms, a control arm with Peg-IFN alfa-2a and ribavirin for
48 weeks (n = 40), and two arms with a 12 week lead-in mono-
therapy with NTZ followed by a 36 week course of NTZ in combi-
nation with pegylated interferon with (n = 28) or without
ribavirin (n = 28). SVR rates in the control arm were only 50%,
which is relatively low as compared to most other previous
HCV-4 trials [140]. Importantly, 79% of the patients receiving tri-
ple therapy with NTZ and PEG-IFN/RBV achieved a SVR that
reached statistical signiﬁcance although patients in the triple
therapy arm were treated for only 36 weeks with PEG-IFN. Of
note, patients receiving NTZ and PEG-IFN without RBV also
showed a surprisingly high SVR of 61%. Although these data are
promising, several issues need to be considered, for example
the rather small overall number of patients with only ﬁve of
the 96 patients having advanced ﬁbrosis or cirrhosis (Ishak S
F4-6) [141]. In addition, there were some differences in patient
characteristics between the study arms as the body mass index
(BMI) was signiﬁcantly lower in patients who received PEG-IFN,
RBV, and NTZ as compared to the control group. This also could
have contributed to the better response in the triple therapy
arm although the BMI was not an independent factor associated
with SVR. Nevertheless, it is quite obvious that further studies are
needed to investigate NTZ in genotype 4 patients. The antiviral
efﬁcacy of NTZ was conﬁrmed during the 12 week lead-in phase
when NTZ was administered alone. NTZ induced a modest but
signiﬁcant HCV-RNA decline of 0.27 log10, which is in line with
the previous monotherapy study [93]. However, only two out of
53 patients treated with NTZ monotherapy had a decline of more
than 1 log10 and just one patient achieved a complete response
(HCV-RNA negative) after 12 weeks, which is in contrast to a pre-
vious trial where six out of 23 patients (26%) were HCV-RNA-neg-
ative after 12 weeks [141]. Thus, it is very unlikely that NTZ
monotherapy will play any role in future treatment of chronic
hepatitis C.
The cyclophilin inhibitior Debio 025 inhibits HCV replication
by inhibiting endogenous cyclophilin and interaction with the
NS5B polymerase, but without immunosuppressive activity. For
treatment-naïve HCV-1 monoinfected patients a reduction of
HCV-RNA of up to 4.75 log10 after 29 days of combination therapy
with Debio 025, PEG-IFN alfa-2a, and ribavirin was shown [142].
Two HCV-4 patients were treated underin this study, one of them
ose in a Debio 025 monotherapy arm. With a dose of 1000 mg per
day the mean viral load reduction after 29 days was
2.2 ± 2.4 log10 for the 12 patients in that arm (11 patients with
genotype 1, one with HCV-4). Importantly, the one genotype-4
patient also had a viral load decline of >2 log10 [142]. Finally, sil-
ibinin, for which the mechanism of action is not yet entirely
resolved, administered intravenously (20 mg/kg/day) for 7 days,1258 Journal of Hepatology 2011led to a mean decline of the HCV-RNA concentration by
3 log10 IU/ml. So far, mainly genotype 1 and single patients with
genotype 2, 3, and 4 infections have been investigated and no
data on differences of antiviral activities for the different HCV
genotypes are available [143]. Recently, Beinhardt et al. reported
a case that the use of silibinin IV are associated with prevention
of graft re-infection in a patient infected with mixed genotype 1a/
4. [144].
The available data on NTZ is are promising, but has need to be
conﬁrmed in larger studies. Other new compounds have been
shown to suppress viral load inHCV-4 patients in proof-of-concept
studies. Further larger trials on the combination of new com-
poundswith PEG-IFN and RBV are needed to explore the beneﬁcial
effect in terms of SVR improvement in patients with HCV-4.
Conclusions
In recent years the study of HCV kinetics under therapy has been
found to be extremely useful to guide the appropriate duration of
therapy, motivate the patient and improve the cost/effectiveness
of treatment. By the application of the RVR, as well as of the com-
plete (cEVR) and partial early responses (pEVR), the duration of
therapy can be individualized between 24 and 48 weeks. In this
context it has become clear that in HCV genotype 4 – similar to
genotype 1, 2, and 3 – a response guided duration of combination
therapy is becoming the current standard of care.
The ongoing spread of HCV-4 to European and other countries
is expected to facilitate further therapeutic studies including
promising drugs like NTZ and direct acting antiviral agents spe-
ciﬁcally targeted to the proteins of HCV genotype 4.vol. 54 j 1250–1262
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